TABLE 1.
Demographic, clinical, endoscopic, and histologic features of the cohort.
| EoE-PPI-TS (n = 14) | ||||||
|---|---|---|---|---|---|---|
| Non- responder (n = 7) |
Responder (n = 7) |
Control (n = 9) |
p value | |||
| A | B | C | A vs. B | A VS. C | B VS. C | |
| Age (years)a | 12 (10–15) | 14 (8–15) | 14 (11–15) | NS | NS | NS |
| Ethnicityb | ||||||
| White | 6 (86) | 6 (86) | 9 (100) | NS | NS | NS |
| Others | 1 (14) | 1 (14) | 0 (0) | NS | NS | NS |
| Maleb | 6 (86) | 5 (71) | 4 (44) | NS | NS | NS |
| Weight (kg) | 57 (30–67) | 54 (32–77) | 64 (46–67) | NS | NS | NS |
| Indication for EGDb | ||||||
| Nausea | – | 1 (14) | 2 (22) | – | – | NS |
| Abdominal pain | – | 1 (14) | 6 (67) | – | – | 0.005 |
| Swallowing difficulties | – | – | 2 (22) | – | – | – |
| Known EoE | 7 (100) | 7 (100) | – | NS | – | – |
| Atopic comorbidityb | ||||||
| Food allergy | 6 (86) | 3 (43) | 3 (33) | NS | 0.03 | NS |
| Allergic rhinitis | 5 (71) | 7 (100) | 1 (11) | NS | <0.001 | <0.001 |
| Asthma | 3 (43) | 5 (71) | 1 (11) | NS | NS | <0.001 |
| Atopic dermatitis | 3 (43) | 4 (57) | 2 (22) | NS | NS | NS |
| Medicationsb | ||||||
| Exposure | ||||||
| Nasal steroids | 4 (57) | 3 (43) | 2 (22) | NS | NS | NS |
| Proton-pump inhibitors | 7 (100) | 7 (100) | – | NS | – | – |
| Topical steroids | 7 (100) | 7 (100) | – | NS | – | – |
| Dosea | ||||||
| Proton-pump inhibitors (mg/kg/day) | 0.64 (0.56–1.33) | 0.62 (0.52–1.01) | 0 | NS | – | – |
| Topical steroids (mg/day) | 1 (1–2) | 1 (1–2) | 0 | NS | – | – |
| EREFSa | 2 (2–3) | 0 (0–0) | 0 (0–0) | NS | NS | NS |
| Number of biopsiesa | 5 (4–6) | 5 (4–6) | 3 (3–4) | NS | NS | NS |
| Peak eosinophil counta | 81 (65–101) | 0 (0–4) | 0 (0–0) | <0.001 | <0.001 | NS |
Abbreviations: EREFS, endoscopic reference score; NS, not significant.
a
Median (interquartile range).
b
Number (percentage).